Apple stock rises after the tech giant posts better-than-expected earnings and guides for solid growth, while Intel’s ...

BofA Securities made an adjustment to the price target for Altria stock, bringing it down to $61 from the previous $65, while still maintaining a Buy rating on the shares. This change was announced by ...

Startup founders are inherently problem solvers. Whether it’s identifying a pain point inside an esoteric industry or building a better mousetrap, almost every journey centers on finding a way to make ...

S-337395 is an investigational oral antiviral candidate for RSV infection that inhibits the activity of the L protein, which is essential for virus replication. 1,2 Furthermore, this drug has received ...

Readers had a lot to say about my latest column on the Food and Drug Administration’s proposed front-of-package labels. Most ...

Shares of Colgate-Palmolive were falling after the consumer products company turned in higher earnings than expected but disappointed investors with its financial guidance. For its fourth quarter, the ...

Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium ...

One of the NPP’s slogans was “Catching Thieves”, a sentiment the people eagerly supported. However, simply putting a “thief ...

A meeting was held at the Ministry of Health, on 28th January 2025, presided by Minister of Health, Dr. Nalinda Jayatissa at ...

The results of a phase 2 trial of MSD’s ROR1 inhibitor zilovertamab vedotin (zilo-V) back up the company's decision to push the antibody-drug conjugate (ADC) into a phase 3 programme.

In an effort to increase homeownership among low and middle income families, Merchant Finance has launched its Zero Deposit ...